当前位置：
X-MOL 学术
›
Lancet Diabetes Endocrinol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
The Lancet Diabetes & Endocrinology ( IF 44.5 ) Pub Date : 2024-02-05 , DOI: 10.1016/s2213-8587(23)00356-x Carel W le Roux , Oren Steen , Kathryn J Lucas , Elena Startseva , Anna Unseld , Anita M Hennige
中文翻译：
胰高血糖素和 GLP-1 受体双重激动剂 survodutide 治疗肥胖症：一项随机、双盲、安慰剂对照、剂量探索 2 期试验
更新日期：2024-02-05
The Lancet Diabetes & Endocrinology ( IF 44.5 ) Pub Date : 2024-02-05 , DOI: 10.1016/s2213-8587(23)00356-x Carel W le Roux , Oren Steen , Kathryn J Lucas , Elena Startseva , Anna Unseld , Anita M Hennige
中文翻译：
胰高血糖素和 GLP-1 受体双重激动剂 survodutide 治疗肥胖症：一项随机、双盲、安慰剂对照、剂量探索 2 期试验
京公网安备 11010802027423号